Displaying 1 - 10 of 10
Immune-Mediated and Cholestatic Diseases
1

Albireo Pharma, an Ipsen Company: “New Horizons in cholestatic liver disease” - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Metabolism, Alcohol & Toxicity
6

Perspectum: Advances in non-invasive imaging for NAFLD / NASH - ILC 2022

View
Metabolism, Alcohol & Toxicity
6

Perspectum: Advances in non-invasive imaging for NAFLD / NASH - ILC 2022

View
Metabolism, Alcohol & Toxicity
6

Perspectum: Advances in non-invasive imaging for NAFLD / NASH - ILC 2022

View
Metabolism, Alcohol & Toxicity
6

Perspectum: Advances in non-invasive imaging for NAFLD / NASH - ILC 2022

View
Metabolism, Alcohol & Toxicity
6

Perspectum: Advances in non-invasive imaging for NAFLD / NASH - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
1

Albireo: Challenges in the Management of Patients with Cholestatic Liver Diseases - Digital ILC 2020

View
Displaying 1 - 10 of 10